Report a pregnancy exposure

VERQUVO^® (vericiguat) may cause birth defects if taken during pregnancy. Females must not be pregnant when they start taking VERQUVO. Females of reproductive potential must use effective forms of birth control during treatment and for 1 month after you stop treatment with VERQUVO. Patients should report any exposure to VERQUVO during pregnancy by calling 1-877-888-4231 or by filling out the form below.

Patients in the United States (U.S.) should report an exposure to VERQUVO during pregnancy by:

Calling 1-877-888-4231 to contact Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Or

Entering contact information below to receive a callback within 1 business day to provide information regarding the pregnancy exposure.

If you are outside of the United States, please contact your local MSD office.

For other inquiries, please contact Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. at 1-800-672-6372

To report an adverse event or product quality complaint in the U.S., please contact the company at 1-800-672-6372. If you are outside the U.S., please contact your local MSD office.